event-icon
Description

Next-generation sequencing is increasingly being used for clinical decision-making in oncology. There is a growing number of genomic testing platforms, genomically-selected trials, and rapidly evolving literature in genomic medicine and molecular oncology. Thus there is a tremendous need for decision support to help health care providers and clinician-investigators. Emerging needs include assistance in accessing, displaying, and interpreting genomic reports, appropriately determining actionability of genomic alterations and identifying approved and investigational therapeutic options. The learning objectives of this panel include determinants of actionability for genomic alterations, needs for decision support in annotations of functional implications of specific alterations and therapeutic implications, and resources and approaches for decision support for genomically-informed therapy.

Learning Objective: After participating in this session, the learner should be better able to:
- Understand the current determinants of actionability, including determining functional implications, and intergrating emerging clinical data
- Learn challenges and possible solutions in creating and maintaining precision oncology knowledgebases focused on gene, drug and trial annotations
- Learn the challenges in clinical trial accrual and strategies for cohort or trial identification

Authors:

Funda Meric-Bernstam (Presenter)
UT-MD Anderson Cancer Center

Matthew Rioth (Presenter)
University of Colorado

Assaf Halevy (Presenter)
2bPrecise

Pete Stetson (Presenter)
Memorial Sloan Kettering Cancer Center

Presentation Materials:

Tags